Pazopanib-Induced Liver Toxicity in Metastatic Renal Cell Carcinoma (mRCC) Patients: Impact of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety and Patient Outcome

Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2019.09.013
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Elsevier BV

Related search

Clinical Outcome of Third-Line Pazopanib in a Patient With Metastatic Renal Cell Carcinoma

Case Reports in Oncological Medicine
Oncology
2015English

Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-Induced Hypertension in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2017English

Pazopanib-Induced Alopecia, an Underestimated Toxicity?

Frontiers in Oncology
Cancer ResearchOncology
2015English

New Advancements and Developments in Treatment of Renal Cell Carcinoma: Focus on Pazopanib

OncoTargets and Therapy
OncologyPharmacology
2010English

Predictors of Long-Term Response With Pazopanib in Patients With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2018English

Pharmacotherapy Options in Advanced Renal Cell Carcinoma: What Role for Pazopanib?

Clinical Medicine Insights: Oncology
Oncology
2011English

Rationale for Targeted Therapies and Potential Role of Pazopanib in Advanced Renal Cell Carcinoma

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2010English

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2019English

Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy